Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Status:
Completed
Trial end date:
2018-10-04
Target enrollment:
Participant gender:
Summary
Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15
mg/mL in subjects with prostate cancer scheduled for prostatectomy.